Published 12 days ago • loading... • Updated 11 days ago

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma

Summary by onclive.com

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

6 Articles

All

Left

Center

Right

Pharmaceutical Business review

FDA to review Regeneron’s linvoseltamab BLA for MM treatment

Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and The post FDA to review Regeneron’s linvoseltamab BLA for multiple myeloma treatment appeared first on Pharmaceutical Business review.

11 days ago

Read Full Article

healthcare-in-europe.com

Multiple myeloma: dangerous diversity

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body:

11 days ago

Read Full Article

cancernetwork.com

FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

12 days ago

Read Full Article

targetedonc.com

FDA Reviews Linvoseltamab in Relapsed/Refractory Multiple Myeloma

The FDA has accepted the resubmitted biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma in heavily pretreated adults.

12 days ago

Read Full Article